Skip to main content
Back to Discussions

What should we consider when discussing new treatments for primary sclerosing cholangitis?

Healthcare
Global
Started October 03, 2026

We welcome the correction to the Seminar by Erik von Seth and colleagues,1 which clarifies that no vancomycin-resistant enterococci were found in published studies of patients with primary sclerosing cholangitis treated with oral vancomycin. The incidence reported initially in the Seminar (8·7%) has been corrected to 0%.1

Source Articles

Add Statement Analysis 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
10 statements to vote on • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Posted by admin • Oct 03, 2026
Informed consent processes for new treatments in primary sclerosing cholangitis must be rigorous to protect patient autonomy.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
Current treatment protocols for primary sclerosing cholangitis should not be altered to include unproven therapies without sufficient evidence.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
The healthcare system should prioritize the development of multidisciplinary care approaches for patients with primary sclerosing cholangitis.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
New treatment options for primary sclerosing cholangitis should be evaluated based on robust, peer-reviewed evidence before widespread implementation.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
Research funding for primary sclerosing cholangitis must prioritize novel therapies that address the underlying disease mechanisms.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
Access to clinical trials for new treatments must be expanded to provide more options for patients with primary sclerosing cholangitis.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
Absence of vancomycin-resistant enterococci in published studies does not guarantee safety in larger or longer-term clinical use.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
Medical literature corrections must be transparently communicated to clinicians and patients, since treatment decisions depend on accurate safety data.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
The promotion of oral vancomycin without comprehensive long-term safety data poses significant risks to patients with primary sclerosing cholangitis.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results
CLAIM Posted by admin • Oct 03, 2026
The costs associated with new treatments for primary sclerosing cholangitis must be transparently communicated to patients and healthcare providers.
Vote options for this statement: agree, disagree, or unsure
💬 View Discussion
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us